AbbVie didn’t just engineer blockbuster drugs—it engineered a blockbuster tax strategy. From 2017 to 2024, the company funnelled billions in profits through a global conveyor belt of intellectual property and low-tax jurisdictions, with Ireland at the centre. The result? Tax bills that veered into the negative—and profits parked far from where they were earned.
TCJA: The Green Light for Global Games
The 2017 U.S. Tax Cuts and Jobs Act (TCJA) was a watershed moment. It slashed the corporate tax rate from 35% to 21%, but more importantly, it moved the U.S. to a quasi-territorial system. That meant U.S. multinationals could keep foreign earnings offshore permanently with minimal U.S. tax—so long as they structured things just right.
AbbVie did exactly that.
By 2018, the company’s effective tax rate turned negative: –9.4%. In the same year, only 1% of its pre-tax income was booked in the United States—even though more than 75% of sales came from the U.S. The rest? Shifted to tax havens like Bermuda and, critically, Ireland.
The TCJA’s “GILTI” provision (Global Intangible Low-Taxed Income) was supposed to stop exactly this kind of avoidance by taxing foreign profits with low effective rates. But AbbVie’s structure let it sidestep the full brunt. In 2018, GILTI added about 8 percentage points to AbbVie’s rate—yet this was dwarfed by a 28-point reduction from foreign income routing. Translation: TCJA offered new rules, but AbbVie was already writing the playbook.
Ireland: IP Capital of the Empire
Ireland wasn’t just a footnote—it was the fulcrum of AbbVie’s international tax plan. When AbbVie acquired Allergan in 2020, it also acquired Allergan’s Ireland-based tax structure. The real prize? Intellectual property.
In the wake of the deal, AbbVie moved IP internally, exploiting Ireland’s favourable tax regime. The result: a $1.7 billion tax benefit from intra-group transfers in 2020 alone. That single manoeuvre slashed its effective tax rate into negative territory again.
This wasn’t about product pipelines—it was about patent pipelines. By shifting IP to Irish subsidiaries and stepping up tax basis, AbbVie generated one-off accounting benefits and set itself up for low-tax income streams in the future. That’s financial engineering at its finest.
Ireland made it easy. With a 12.5% corporate rate and generous rules for tax-deductible amortisation of IP, it became the preferred destination for AbbVie’s intangibles. From there, Irish entities could charge royalties to affiliates elsewhere—extracting profits globally while incurring minimal local tax.
The Transfer Pricing Machine
Between 2018 and 2022, AbbVie’s core engine was simple: book U.S. revenues, but shift the profits to Ireland.
How did it work? Through transfer pricing. AbbVie assigned ownership of the license to its most valuable IP assets—its drug patents—to Irish subsidiaries. These Irish entities then licensed the rights back to AbbVie’s U.S. operations. As a result, the American affiliates had to pay hefty royalties to Ireland for the right to sell the drugs, especially its blockbuster, Humira. Those royalty payments were recorded as expenses in the U.S., shrinking domestic taxable income. Meanwhile, the same payments were booked as revenue in Ireland—where they were taxed at a much lower rate.
This is how AbbVie could earn tens of billions in the U.S., but report tax rates of 6%, 11%, 12%—well below even the reduced U.S. statutory rate post-TCJA. Every year, the company’s filings pointed to “foreign operations in jurisdictions with lower tax rates” as the reason. Read: profits went to Ireland.
And the tax team didn’t stop there. They piled on credits—R&D, orphan drug, and Puerto Rico excise tax credits—knocking a few more points off the tax rate each year.
When Avoidance Pays Off (Literally)
The cherry on top came in 2024. AbbVie closed out years of IRS audits, releasing over $2 billion in tax reserves. These were liabilities it had previously booked in case its tax positions failed. But they didn’t. AbbVie won. The result? Another –10+% effective tax rate.
These victories reflect more than just Irish good luck—they’re the payoff from years of aggressive, calculated positions around IP ownership, transfer pricing, and international structuring. The company took the gamble that its Irish profit shifting would hold up under scrutiny—and it did.
AbbVie’s effective tax rate consistently defied the norm—at times plunging below zero—thanks to meticulous tax structuring around IP and international income.
Conclusion: Pharma Profits, Irish Margins
The evidence is clear: from 2017 to 2024, AbbVie’s tax strategy was built on the strategic deployment of intellectual property, international profit shifting, and precise navigation of post-TCJA tax rules. Ireland was the keystone.
AbbVie didn’t just use Ireland as a base—it embedded IP there, realigned its global profit chain, and kept the majority of its income offshore while minimising GILTI exposure. The TCJA gave AbbVie more room to manoeuvre, and it used every inch of it.
Forensic accounting leaves no doubt: AbbVie’s low tax bills weren’t a happy accident. They were architected. And Ireland was the blueprint. Nobody should be surprised that Donald Trump wants to put an end to this.
Leave a Reply